AR038765A1 - Formulacion en solucion inhalable con una sal de tiotropio - Google Patents
Formulacion en solucion inhalable con una sal de tiotropioInfo
- Publication number
- AR038765A1 AR038765A1 ARP010105088A ARP010105088A AR038765A1 AR 038765 A1 AR038765 A1 AR 038765A1 AR P010105088 A ARP010105088 A AR P010105088A AR P010105088 A ARP010105088 A AR P010105088A AR 038765 A1 AR038765 A1 AR 038765A1
- Authority
- AR
- Argentina
- Prior art keywords
- phenyl
- water
- preparation according
- tiotropium
- drug preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased/Invalidation/Refusal/Rejection/Nullification
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 238000009472 formulation Methods 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 title abstract 2
- 239000013543 active substance Substances 0.000 abstract 5
- 239000003814 drug Substances 0.000 abstract 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 4
- 229940079593 drug Drugs 0.000 abstract 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 4
- 239000003380 propellant Substances 0.000 abstract 3
- LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical class O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 abstract 3
- 239000002253 acid Substances 0.000 abstract 2
- 239000000043 antiallergic agent Substances 0.000 abstract 2
- 239000000739 antihistaminic agent Substances 0.000 abstract 2
- 239000003199 leukotriene receptor blocking agent Substances 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 239000003755 preservative agent Substances 0.000 abstract 2
- 150000003431 steroids Chemical class 0.000 abstract 2
- -1 2 , 3-dichloro-thieno [3,2-b] pyridin-5-yl Chemical group 0.000 abstract 1
- AOPATQAZIRXNOX-UHFFFAOYSA-N 2-(1-methylcyclopropyl)acetic acid Chemical compound OC(=O)CC1(C)CC1 AOPATQAZIRXNOX-UHFFFAOYSA-N 0.000 abstract 1
- PSILZZNMGXTOOP-UHFFFAOYSA-N 2-[2-[[2-(4-tert-butyl-1,3-thiazol-2-yl)-1-benzofuran-5-yl]oxymethyl]phenyl]acetic acid Chemical compound CC(C)(C)C1=CSC(C=2OC3=CC=C(OCC=4C(=CC=CC=4)CC(O)=O)C=C3C=2)=N1 PSILZZNMGXTOOP-UHFFFAOYSA-N 0.000 abstract 1
- KVVDRQDTODKIJD-UHFFFAOYSA-N 2-cyclopropylacetic acid Chemical compound OC(=O)CC1CC1 KVVDRQDTODKIJD-UHFFFAOYSA-N 0.000 abstract 1
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 abstract 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 abstract 1
- LERNTVKEWCAPOY-VOGVJGKGSA-N C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical compound C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 LERNTVKEWCAPOY-VOGVJGKGSA-N 0.000 abstract 1
- HOKDBMAJZXIPGC-UHFFFAOYSA-N Mequitazine Chemical compound C12=CC=CC=C2SC2=CC=CC=C2N1CC1C(CC2)CCN2C1 HOKDBMAJZXIPGC-UHFFFAOYSA-N 0.000 abstract 1
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical group CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 abstract 1
- YEEZWCHGZNKEEK-UHFFFAOYSA-N Zafirlukast Chemical compound COC1=CC(C(=O)NS(=O)(=O)C=2C(=CC=CC=2)C)=CC=C1CC(C1=C2)=CN(C)C1=CC=C2NC(=O)OC1CCCC1 YEEZWCHGZNKEEK-UHFFFAOYSA-N 0.000 abstract 1
- 239000000654 additive Substances 0.000 abstract 1
- 230000000996 additive effect Effects 0.000 abstract 1
- 239000000443 aerosol Substances 0.000 abstract 1
- 229940125715 antihistaminic agent Drugs 0.000 abstract 1
- GXDALQBWZGODGZ-UHFFFAOYSA-N astemizole Chemical compound C1=CC(OC)=CC=C1CCN1CCC(NC=2N(C3=CC=CC=C3N=2)CC=2C=CC(F)=CC=2)CC1 GXDALQBWZGODGZ-UHFFFAOYSA-N 0.000 abstract 1
- 229950000210 beclometasone dipropionate Drugs 0.000 abstract 1
- 229960004436 budesonide Drugs 0.000 abstract 1
- 229960000428 carbinoxamine Drugs 0.000 abstract 1
- OJFSXZCBGQGRNV-UHFFFAOYSA-N carbinoxamine Chemical compound C=1C=CC=NC=1C(OCCN(C)C)C1=CC=C(Cl)C=C1 OJFSXZCBGQGRNV-UHFFFAOYSA-N 0.000 abstract 1
- 229960002881 clemastine Drugs 0.000 abstract 1
- YNNUSGIPVFPVBX-NHCUHLMSSA-N clemastine Chemical compound CN1CCC[C@@H]1CCO[C@@](C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 YNNUSGIPVFPVBX-NHCUHLMSSA-N 0.000 abstract 1
- 230000000536 complexating effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000006184 cosolvent Substances 0.000 abstract 1
- 229960000265 cromoglicic acid Drugs 0.000 abstract 1
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 abstract 1
- 229960003449 epinastine Drugs 0.000 abstract 1
- WHWZLSFABNNENI-UHFFFAOYSA-N epinastine Chemical group C1C2=CC=CC=C2C2CN=C(N)N2C2=CC=CC=C21 WHWZLSFABNNENI-UHFFFAOYSA-N 0.000 abstract 1
- 229960000676 flunisolide Drugs 0.000 abstract 1
- 229960002714 fluticasone Drugs 0.000 abstract 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 229960005042 mequitazine Drugs 0.000 abstract 1
- NMJORVOYSJLJGU-UHFFFAOYSA-N methane clathrate Chemical compound C.C.C.C.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O NMJORVOYSJLJGU-UHFFFAOYSA-N 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 229960005127 montelukast Drugs 0.000 abstract 1
- 229960004398 nedocromil Drugs 0.000 abstract 1
- RQTOOFIXOKYGAN-UHFFFAOYSA-N nedocromil Chemical compound CCN1C(C(O)=O)=CC(=O)C2=C1C(CCC)=C1OC(C(O)=O)=CC(=O)C1=C2 RQTOOFIXOKYGAN-UHFFFAOYSA-N 0.000 abstract 1
- 229960004583 pranlukast Drugs 0.000 abstract 1
- UAJUXJSXCLUTNU-UHFFFAOYSA-N pranlukast Chemical compound C=1C=C(OCCCCC=2C=CC=CC=2)C=CC=1C(=O)NC(C=1)=CC=C(C(C=2)=O)C=1OC=2C=1N=NNN=1 UAJUXJSXCLUTNU-UHFFFAOYSA-N 0.000 abstract 1
- 230000002335 preservative effect Effects 0.000 abstract 1
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 abstract 1
- 229940110309 tiotropium Drugs 0.000 abstract 1
- 229960000257 tiotropium bromide Drugs 0.000 abstract 1
- MQLXPRBEAHBZTK-SEINRUQRSA-M tiotropium bromide hydrate Chemical compound O.[Br-].C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 MQLXPRBEAHBZTK-SEINRUQRSA-M 0.000 abstract 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 abstract 1
- 229960004764 zafirlukast Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Otolaryngology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10054042 | 2000-10-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR038765A1 true AR038765A1 (es) | 2005-01-26 |
Family
ID=7661727
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP010105088A Ceased/Invalidation/Refusal/Rejection/Nullification AR038765A1 (es) | 2000-10-31 | 2001-10-31 | Formulacion en solucion inhalable con una sal de tiotropio |
Country Status (33)
Country | Link |
---|---|
EP (1) | EP1335729A2 (hr) |
JP (1) | JP4559703B2 (hr) |
KR (1) | KR100983208B1 (hr) |
CN (1) | CN1237970C (hr) |
AR (1) | AR038765A1 (hr) |
AU (2) | AU2174102A (hr) |
BG (1) | BG66425B1 (hr) |
BR (1) | BR0115016A (hr) |
CA (1) | CA2427583C (hr) |
CZ (1) | CZ305033B6 (hr) |
DE (1) | DE10152369A1 (hr) |
EA (1) | EA009068B1 (hr) |
EC (1) | ECSP034570A (hr) |
EE (1) | EE05343B1 (hr) |
HK (1) | HK1060569A1 (hr) |
HR (1) | HRP20030337A2 (hr) |
HU (1) | HUP0301377A3 (hr) |
IL (2) | IL155676A0 (hr) |
ME (1) | ME00242B (hr) |
MX (1) | MXPA03003750A (hr) |
MY (1) | MY132777A (hr) |
NO (1) | NO332524B1 (hr) |
NZ (1) | NZ526024A (hr) |
PE (1) | PE20020518A1 (hr) |
PL (1) | PL361001A1 (hr) |
SA (1) | SA01220503B1 (hr) |
SK (1) | SK288031B6 (hr) |
TW (1) | TWI296934B (hr) |
UA (1) | UA76435C2 (hr) |
UY (1) | UY26991A1 (hr) |
WO (1) | WO2002036591A2 (hr) |
YU (1) | YU33103A (hr) |
ZA (1) | ZA200303045B (hr) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA02010565A (es) | 2000-04-28 | 2004-05-17 | Kosan Biosciences Inc | Produccion de policetidos. |
US20030235538A1 (en) | 2002-04-09 | 2003-12-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Method for the administration of an anticholinergic by inhalation |
GB2389530B (en) | 2002-06-14 | 2007-01-10 | Cipla Ltd | Pharmaceutical compositions |
AU2004279438A1 (en) * | 2003-10-09 | 2005-04-21 | Inverseon, Inc. | Methods for treating diseases and conditions with inverse agonists |
SE0303269L (sv) * | 2003-12-03 | 2005-06-04 | Microdrug Ag | Medicinsk produkt |
MX2007011273A (es) * | 2005-03-16 | 2007-11-08 | Meda Pharma Gmbh & Co Kg | La combinacion de anticolinergicos y antagonistas del receptor de leucotrieno para el tratamiento de enfermedades respiratorias. |
EP2034990A4 (en) * | 2006-05-26 | 2013-03-06 | Dey L P | DIRTIBLE COMPOSITIONS OF QUATERNARY AMMONIUM MUSCARIN RECEPTOR ANTAGONISTS |
CN100446770C (zh) * | 2007-01-10 | 2008-12-31 | 上海现代药物制剂工程研究中心有限公司 | 丙酸培氯米松水雾剂 |
TR200907237A2 (tr) * | 2009-09-23 | 2011-04-21 | Bi̇lgi̇ç Mahmut | Tiotropyum kuru toz kombinasyonu |
CN111936124A (zh) * | 2018-07-26 | 2020-11-13 | 四川海思科制药有限公司 | 一种含格隆铵盐及茚达特罗盐的气雾剂药物组合物及其制备方法与应用 |
CN111971034A (zh) * | 2018-07-26 | 2020-11-20 | 四川海思科制药有限公司 | 一种含格隆铵盐的气雾剂药物组合物及其制备方法与应用 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0504112A3 (en) * | 1991-03-14 | 1993-04-21 | Ciba-Geigy Ag | Pharmaceutical aerosol formulations |
DE4203306A1 (de) * | 1992-02-06 | 1993-08-12 | Ig Spruehtechnik Gmbh | Asthma oder pulmonal-aerosolzubereitungen mit lecithin |
DK0835098T3 (da) * | 1995-06-27 | 2002-10-07 | Boehringer Ingelheim Pharma | Stabilt lægemiddelpræparat til frembringlese af drivgasfrie aerosoler |
US5824669A (en) * | 1996-03-22 | 1998-10-20 | Nitromed, Inc. | Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders |
CA2256721A1 (en) * | 1996-06-04 | 1997-12-11 | The Procter & Gamble Company | A nasal spray containing an intranasal steroid and an antihistamine |
DE19653969A1 (de) * | 1996-12-20 | 1998-06-25 | Boehringer Ingelheim Kg | Neue wässrige Arzneimittelzubereitung zur Erzeugung treibgasfreier Aerosole |
JPH10298107A (ja) * | 1997-04-25 | 1998-11-10 | Taisho Pharmaceut Co Ltd | 医薬組成物 |
ATE234604T1 (de) * | 1998-08-04 | 2003-04-15 | Jago Res Ag | Medizinische aerosolformulierungen |
DE19847968A1 (de) * | 1998-10-17 | 2000-04-20 | Boehringer Ingelheim Pharma | Verschlußkappe und Behälter als Zweikammer-Kartusche für Vernebler zur Erzeugung von Aerosolen |
-
2001
- 2001-10-24 AU AU2174102A patent/AU2174102A/xx active Pending
- 2001-10-24 JP JP2002539350A patent/JP4559703B2/ja not_active Expired - Lifetime
- 2001-10-24 CN CNB018183271A patent/CN1237970C/zh not_active Expired - Lifetime
- 2001-10-24 UA UA2003054960A patent/UA76435C2/uk unknown
- 2001-10-24 CA CA002427583A patent/CA2427583C/en not_active Expired - Fee Related
- 2001-10-24 IL IL15567601A patent/IL155676A0/xx unknown
- 2001-10-24 WO PCT/EP2001/012296 patent/WO2002036591A2/de active IP Right Grant
- 2001-10-24 NZ NZ526024A patent/NZ526024A/en not_active IP Right Cessation
- 2001-10-24 MX MXPA03003750A patent/MXPA03003750A/es active IP Right Grant
- 2001-10-24 SK SK526-2003A patent/SK288031B6/sk not_active IP Right Cessation
- 2001-10-24 YU YU33103A patent/YU33103A/sh unknown
- 2001-10-24 EA EA200300483A patent/EA009068B1/ru not_active IP Right Cessation
- 2001-10-24 DE DE10152369A patent/DE10152369A1/de not_active Withdrawn
- 2001-10-24 AU AU2002221741A patent/AU2002221741B2/en not_active Expired
- 2001-10-24 HU HU0301377A patent/HUP0301377A3/hu unknown
- 2001-10-24 CZ CZ2003-1487A patent/CZ305033B6/cs not_active IP Right Cessation
- 2001-10-24 ME MEP-2008-407A patent/ME00242B/me unknown
- 2001-10-24 PL PL01361001A patent/PL361001A1/xx not_active Application Discontinuation
- 2001-10-24 EE EEP200300202A patent/EE05343B1/xx unknown
- 2001-10-24 EP EP01992710A patent/EP1335729A2/de not_active Ceased
- 2001-10-24 KR KR1020037006001A patent/KR100983208B1/ko active IP Right Grant
- 2001-10-24 BR BR0115016-2A patent/BR0115016A/pt active Pending
- 2001-10-29 TW TW090126752A patent/TWI296934B/zh not_active IP Right Cessation
- 2001-10-29 MY MYPI20014987A patent/MY132777A/en unknown
- 2001-10-29 PE PE2001001072A patent/PE20020518A1/es active IP Right Grant
- 2001-10-29 UY UY26991A patent/UY26991A1/es not_active Application Discontinuation
- 2001-10-31 AR ARP010105088A patent/AR038765A1/es not_active Ceased/Invalidation/Refusal/Rejection/Nullification
- 2001-11-03 SA SA01220503A patent/SA01220503B1/ar unknown
-
2003
- 2003-04-16 BG BG107726A patent/BG66425B1/bg active Active
- 2003-04-17 ZA ZA200303045A patent/ZA200303045B/xx unknown
- 2003-04-28 HR HR20030337A patent/HRP20030337A2/hr not_active Application Discontinuation
- 2003-04-28 EC EC2003004570A patent/ECSP034570A/es unknown
- 2003-04-29 NO NO20031914A patent/NO332524B1/no not_active IP Right Cessation
- 2003-04-30 IL IL155676A patent/IL155676A/en active IP Right Grant
-
2004
- 2004-05-20 HK HK04103587A patent/HK1060569A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6890517B2 (en) | Inhalable formulation of a solution containing a tiotropium salt | |
JP7015331B2 (ja) | ロフルミラストn-酸化物の吸入によって自己免疫、呼吸器性および炎症性の障害を処置する方法 | |
ES2276942T3 (es) | Combinacion de un inhibidor de pde4 y tiotropio o un derivado del mismo para tratar vias respiratorias obstructivas y otras enfermedades inflamatorias. | |
AR038765A1 (es) | Formulacion en solucion inhalable con una sal de tiotropio | |
UA64736C2 (uk) | Лікарський препарат у формі водного розчину | |
EA014776B1 (ru) | Фармацевтическая композиция для аэрозольного распыления с двумя действующими веществами и по меньшей мере одним поверхностно-активным веществом | |
RU2361593C3 (ru) | Комбинация азеластина и стероидов | |
JP2008500990A5 (hr) | ||
BRPI0618643A2 (pt) | composição compreendendo um par de fármacos, composição compreendendo um corticosteróide e um imunossupressor dependente de imunofilina não-esteróide, kits e uso | |
PE20060826A1 (es) | Derivado oleofinico de 8-azoniabiciclo[3.2.1]octano y combinacion farmaceutica que lo comprende | |
ES2727526T3 (es) | Combinaciones que comprenden compuestos MABA y corticosteroides | |
PE20080607A1 (es) | Formulacion en aerosol para la inhalacion de beta-agonistas | |
JP2009526064A (ja) | 薬学的調合物 | |
JP2004538267A (ja) | 閉塞性気道疾患及びその他の炎症性疾患を治療するためのドーパミンd2−受容体アゴニスト及びチオトロピウム又はその誘導体の組み合わせ | |
KR20110123740A (ko) | 5-(2-{[6-(2,2-디플루오로-2-페닐에톡시)헥실]아미노}-1-히드록시에틸)-8-히드록시퀴놀린-2(1h)-온 및 이의 폐질환 치료에서의 용도 | |
CN103857394A (zh) | 四氢甲基嘧啶羧酸的治疗应用 | |
US20030064034A1 (en) | Use of compounds in a dry powder inhaler | |
AU2017225140A1 (en) | Pi3k inhibitor for treatment of respiratory disease | |
CN103736093A (zh) | 一种包含咪唑斯汀及甾族化合物的药物制剂 | |
ES2670018T3 (es) | Nuevos compuestos | |
BR102012008322A2 (pt) | Formulações medicinais em aerossol que não debilitam a camada de ozônio e com baixo efeito estufa |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |